Breadcrumb Home Sovaldi Finance Editorial: The unaffordable cost of M&A-driven drug prices Government Spending on prescription drugs under the Medicare Part D program increased more than 17% in 2014 despite a claims increase of just 3%, and other news Finance Lower Harvoni sales dampen Gilead's second-quarter profit Government Massachusetts Medicaid secures rebates for hepatitis C drugs Technology FDA approves first pill to treat all forms of hepatitis C Finance Patently perturbed: Trans-Pacific Partnership trade deal raises fears about drug patent periods, higher costs Finance Institutional investors fight for more sway at healthcare companies Finance Gilead paying up to $1.2B for Nimbus unit, drug, technology Government Editorial: Keep CMS' value-based pay off my Medicare drugs! Providers Could Massachusetts have the tool to fix high drug costs? Load More Sponsored Content
